Pfizer Investigational Antibiotic Combination Demonstrates Efficacy Against Gram-Negative Infections
June 14th 2023In phase 3 studies, the company’s investigational therapy, aztreonam-avibactam (ATM-AVI), had favorable results over other treatments used for complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), and ventilator-associated pneumonia (VAP).
COVID-19 Rebound Found More in Hospitalized Patients With Existing Health Problems
June 9th 2023A new retrospective study found non-oxygen-dependent COVID-19 patients were more likely to experience this phenomenon if they were immunocompromised, receiving concomitant corticosteroids, or had comorbidities.
IDSA Releases Treatment Guidance for Antimicrobial Resistant Gram-Negative Infections
June 8th 2023The update includes several different infections, and offers brief descriptions of significant clinical trials, resistance mechanisms, and antimicrobial susceptibility testing methods for each of the pathogens.
Challenging the Status Quo: Oral Transitional Therapy for Infective Endocarditis
June 8th 2023New evidence suggests that oral transitional therapy may be a promising option for the treatment of infective endocarditis (IE). A retrospective cohort study reveals comparable clinical outcomes between oral and intravenous antibiotic regimens.
Building a C Diff Community and Advocating for Survivors and Caregivers
June 7th 2023The Peggy Lillis Foundation (PLF) for C diff Education & Advocacy has been working to help people affected by the healthcare associated infection and getting involved with public advocacy including their support of the prospective antibiotic-related law, the Pasteur Act.
COVID-19 Public Health Emergency Is Over. What Have We Learned?
June 7th 2023As the official COVID-19 emergency is declared over, our Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reflects on the public health response, the scientific successes, and the shortcomings that were experienced.